Email piyush.patel@visiongain.com for early bird discount

1. 5th Annual
Recombinant Antibodies
Advances in bispecific, next-generation and monoclonal antibody development and translation
17th – 19th January, 2012, Visiongain Conference Centre, London, UK BOOK NOW!
Key Speakers
Paulo Fontoura, Global Head CNS Translational Medicine, F. Hoffmann-La Roche
Jennifer Sims, Global Head of Biologics Safety & Disposition, Novartis
Ulrich Brinkmann, Scientific Director, Biologics Engineering, Roche Pharma Research and Early Development
Matthew Sleeman, Director of Biology, MedImmune
Lolke de Haan, Director of Toxicology, Biologics Safety Assessment, MedImmune
Andrew Nesbitt, Associate Director, Cimzia Mechanism of Action Group, UCB Celltech
Jürgen Michael Schanzer, Research Scientist Biologics Engineering, Roche Diagnostics
Maria A.T. Groves, Senior Scientist, Lead Generation, ADPE, MedImmune
John McCafferty, Director of Research, University of Cambridge
Kerry Chester, Professor Molecular Medicine, University College London
Christian Rohlff, Chief Executive Officer, Oxford BioTherapeutics
Matthew Baker, Chief Scientific Officer, Antitope
Nicolas Fischer, Head of Research, NovImmune
Lihui Xu, Group Leader, Antibody Technology and Generation, Merrimack Pharmaceuticals
Pre-conference Workshop, Tuesday 17th January, 2012
Antibody drug conjugates– finally delivering their payload
Led by: Shane Olwill, Senior Director R&D, Pharmacology, Pieris
Organised By
Driving the Industry Forward | www.futurepharmaus.com
Media Partners
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/rabs

2. Conference Introduction
5th Annual Recombinant Antibodies
17th - 19th January 2012, London, UK
Dear Colleague, Media Partners:
rom Kohler and Millstein’s pioneering efforts to today’s multifactorial approach,
F PharmiWeb.com is the leading industry-sponsored portal for
monoclonal antibodies have consistently improved the clinical outcome of disease the pharmaceutical sector. Supported by most of the leading
progression. As shown by Avastin and Lucentis, antibodies have blockbuster potential, now pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features,
number eight of today’s 20 top-selling biotech drugs. With ongoing growth rates nearing events listings and international jobs to industry professionals across Europe and the US.
15%, the global market will reach $80 by 20251 as new approvals and a growing world For further information please email: corporate@pharmiweb.com
population drive patient demand. BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
ith over 25 products approved for human use and 26 candidates in Phase III trials,
W WORLD. It is based and located in Warsaw, Poland.
mAbs remain arguably the most exciting proteins today. Pharmaceutical companies have Biotechnology World was founded in 2007 to provide the
become more interested, especially in fully-human, bi-specific and scFv proteins, as these world’s biotech and pharma information and market to make it universally accessible
progress through development for new indications including ophthalmic, autoimmune and useful for scientific and business processes. Its first step to fulfilling that mission
was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread
and viral diseases. of information in different channels. BIOTECHNOLOGY EUROPE offers companies
ith competition intensifying, rational design to target multiple disease pathways has
W completed internet public relations, publication and marketing solutions. One of the
become ever more important in an increasingly crowded market. This includes utilising mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma
informatics, omics, and systems biology insights. Decreasing immunogenicity, improving Sector in Europe to global biotechnology, pharmaceutical and life science activities.
receptor-ligand interactions and decreasing in vivo clearance rates remain ongoing For further information please visit: www.biotechnology-europe.com
challenges, as do more effective biodistribution, targeting, tissue penetration and uptake. Future Pharmaceuticals has forged powerful relationships with
Driving the Industry Forward | www.futurepharmaus.com
Addressing these needs, Visiongain’s Fifth Annual Recombinant key industry leaders to provide a platform for successful brand
recognition, and for senior decision-makers to have the means
Antibodies conference showcases how such goals are being met to procure and plan implementation strategies based on the topics covered. Positioned
by leading experts. Whether your interests lie in basic, pre-clinical, to be an authoritative resource within top pharma companies as well as small,
translational or clinical research, business diversification, licensing or specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep
partnering, attending this conference will empower you to: penetration into a highly targeted and responsive audience, bridging the gap between
• etwork with key decision makers at leading companies including Roche, Novartis and
N the industries’ top issues and the solutions top-tier vendors can provide.
MedImmune For further information please visit: www.futurepharmaus.com
• Improve the potency of IgG molecules for ADCC, ADCP and CDC applications InPharm is the online platform for exclusive pharmaceutical
• Enhance immune effector functions through targeted Fc region engineering news, comment, contracts, services, jobs and events and is
home to InPharmjobs.com, Pharmafile and Pharmafocus.
• Increase in vivo circulation time with conjugated immunoglobulins
• Extend pharmacokinetic half-life and exposure
For further information please visit: www.inpharm.com
• Better utilise, deploy and evaluate in silico tools during early-phase research
• Optimise antigen-binding domains
• Engineer decreased immunogenicity, cross-reactivity and in vivo toxicity
• Assess new technologies for selecting antibody attributes Poster Presentation
• Maximise site-specific drug loading for bispecific antibodies At a busy conference it is hard to make sure everyone who shares your interests knows
• btain new data on inflammatory disease, and solid and liquid cancer targets
O what you are doing. Maximise your time at Visiongain’s 5th Annual Recombinant
• lock activation of angiogenic signalling pathways and disrupt the tumour
B Antibodies meeting by sharing your results in a poster presentation. With a plethora of key
microenvironment decision makers, take advantage of this senior networking opportunity.
I look forward to meeting you at the conference Please send your 200 word abstract, in English, to: info@visiongainglobal.com for
Best regards approval. The deadline for submissions is Tuesday, 10th January, 2012. Please include
contact details for the corresponding author(s).
Academic institutions will not be charged a fee if booked as full-price delegates. Posters
submitted by pharmaceutical and biotechnology firms will be charged a fee of £199.
Posters submitted by service providers / vendors are welcome and will be subject to
Nicholas Stone evaluation. Upon approval a fee of £500 will apply. Two delegates from your organisation
Head of Conferences must be booked at full price to present a poster.
Please note that all posters will be displayed at the discretion of Visiongain Ltd and are
subject to approval. Due to limited space, please register your interest early.
Who should attend?
Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents,
Professors, Heads, Directors, Principal/Senior Scientists and Managers/Team
Leaders of:
• Antibody design, production and development
Sponsorship and exhibition opportunities
• Recombinant DNA/molecular biotechnology This event offers a unique opportunity to meet and do business with some of the key
• Protein/biochemical engineering
• Biotherapeutics players in the pharmaceutical and biotech industries. If you have a service or product
• Assay and cell display technologies
to promote, you can do so at this event by:
• Bio-analytical and protein-analytical R&D, and analytical chemistry
• Process development • Hosting a networking drinks reception
• Preclinical/clinical research and development
• Oncology • Taking an exhibition space at the conference
• CNS, autoimmune and inflammatory disease research • Advertising in the delegate documentation pack
• Arthritis, colorectal/breast/lymphoma/prostate/lung cancer R&D
• Immunobiology and immunogenicity testing • Providing branded bags, pens, gifts, etc.
• Pharmacovigilance
If you would like more information on the range of sponsorship or exhibition possibilities
• Business and alliance development
• Marketing and licensing for visiongain's 5th Annual Recombinant Antibodies Conference, please contact us:
• Biosimilars
• Contract manufacturing and research organisations Damian Gorman, +44 (0)20 7549 9934
• Regulatory affairs, pharmaceutical and patent law
• Pharmaceutical and patent law damian.gorman@visiongainglobal.com
Visiongain, (2010). Therapeutic Monoclonal Antibodies: World Market 2010-2025
1

3. Pre-Conference Interactive Workshop
5th Annual Recombinant Antibodies
Tuesday 17th January 2012
Antibody drug conjugates– finally delivering their payload
Led by: Shane Olwill Timings: 9:30 - 10:00 Coffee & Registration
0
Senior Director R&D, Pharmacology 10:00 - 15:00 Workshop
Pieris T
iming includes lunch and refreshment breaks
Agenda: About your workshop leader:
The development of antibody drug conjugates (ADCs) has faced
Dr Shane Olwill
considerable hurdles over the past decade with research efforts
hampered by target selection, optimal antibody format, conjugation Dr Shane Olwill has spent over a decade in oncology-focused drug
chemistries, bioprocessing and choice of drug payloads. However, a new
discovery, with a specific interest in the development of novel biologics.
wave of optimism has emerged following successful clinical trial data
At Pieris, Shane is responsible for managing preclinical oncology
from lead compounds such as TDM-1 (ImmunoGen – Roche/Genentech)
in breast cancer and SGN35 (Seattle Genetics-Millennium/Takeda) being programs from discovery into the clinic. He is also responsible for
evaluated for the treatment of Hodgkin’s lymphoma. This has led to a characterizing ADC applications of anticalins. Prior to joining Pieris,
heightened level of interest in the area.
Shane was Director of Research at Fusion Antibodies Ltd. Shane received
This workshop will provide an introduction to the development of ADCs
his B.Sc. in Biomedical Sciences and Ph.D. in Molecular Haematology/
including key selection criteria for ADC components. It will review the
current status of ADCs in development, discussing how they can aid the Oncology from the University of Ulster.
delivery of potent anti-neoplastic molecules with reduced toxicity and
improve the therapeutic index when compared to naked antibodies. The About: Pieris. The Anticalin Company™
workshop will also introduce how next generation non-IgG scaffolds such
as Anticalins may further enhance their therapeutic index.
Pieris AG is an independent clinical stage biotechnology company that is
dedicated to the discovery and development of life changing drugs. Our
proprietary technology, the Anticalin® technology, encompasses a novel
About visiongain:
Visiongain is a specialist business information company focused on class of therapeutic proteins that addresses a broad range of therapeutic
providing cutting edge products and services across the Pharmaceutical/
applications and targets. Pieris has a growing, exciting and differentiated
Biotech, Telecommunications, Defence and Finance sectors, which
include reports, conferences, online daily news and offline news drug pipeline across multiple disease areas. Pieris will commercialize
analysis and bespoke consultancy. With a commitment to innovation
Anticalin therapeutics through strategic partnerships, involving both
and excellence, visiongain offers flexible solutions to meet our clients’
business intelligence needs, providing the right information at the its proprietary pipeline and its de novo drug discovery capabilities. The
right time to facilitate the commercial decision-making process. Our
company has four ongoing discovery and development collaborations:
pharmaceutical products include Pharma Business Daily, the leading
daily email newsletter for the pharmaceutical, biotech and healthcare Daiichi Sankyo, Takeda San Francisco, Allergan, Sanofi-Aventis and Sanofi-
industries, and a range of independent, high-quality, in-depth reports Pasteur. Pieris is well financed, having closed Series A and B rounds
covering focused and topical areas of concern. Our pharmaceutical
conferences address the hottest commercial, regulatory and technical of venture-backed financing, led by Global Life Science Ventures and
topics and provide an ideal forum for debate and networking for OrbiMed Advisors.
pharmaceutical professionals from around the world.
For further information, please visit: www.visiongain.com For further information, please visit: www.pieris-ag.com

4. Day 1
5th Annual Recombinant Antibodies
Wednesday 18th January 2012
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the Chairs 13:40 Bispecific antibodies for targeted payload delivery
Kerry Chester • Generation & optimisation of hapten-binding bispecific antibodies
Professor Molecular Medicine
• Complexation and targeted delivery of haptenylated payloads
University College London
• Targeted payload delivery in vitro and in vivo
Matthew Sleeman
Director of Biology Ulrich Brinkmann
MedImmune Scientific Director, Biologics Engineering
Roche Pharma Research and Early Development
09:40 Biology of Fc receptors: impact on
therapeutic antibodies 14:20 Rational engineering of antibody therapeutics
• Functional importance of FcγRs targeting multiple oncogene pathways
• D20 therapeutic antibodies depend on immune cell Fc
C • olecular format and pharmaceutical properties in bispecific
M
receptor interactions antibody design
• Tumour burden determines the effector mechanism of CD20 antibodies • Identifying best targets and optimal design characteristics
• Engineering a bispecific antibody through a therapeutic design cycle
Jeanette Leusen
Associate Professor Lihui Xu
University Medical Centre Utrecht Group Leader, Antibody Technology and Generation
Merrimack Pharmaceuticals
10:20 Antibody engineering by design
• PK and receptor occupancy models to future-proof antibody design 15:00 Afternoon refreshments
• Harnessing the power of phage display to meet specific design criteria
• ombining biology, pharmacology and PD to translate preclinical
C 15:20 PASylation: a superior approach to engineer
observations into the clinic antibody fragments with extended plasma half-life
• Phase I clinical results and their relation to the theoretical model • c fusion, HSA fusion and PEGylation strategies to achieve
F
Matthew Sleeman prolonged circulation
Director of Biology • ASylation (genetic fusion with a long disordered polypeptide comprising
P
MedImmune Pro, Ala and Ser residues) as an alternative
• reclinical applications of PASylation for Fab fragments and other
P
11:00 Morning refreshments biopharmaceuticals
Arne Skerra
11:20 Development of tetravalent, bispecific CCR5 Managing Director
antibodies with antiviral activity against CCR5 XL-protein
monoclonal antibody-resistant HIV-1 strains
• Construction of a novel tetravalent, bispecific antibody to block HIV entry
• esign optimisation of scFvs including disulfide and increased linker
D 16:00 Monoclonal and next-generation antibodies- where
length stabilization are we and what are the prospects for the future?
PANEL DISCUSSION
• nhanced antiviral potency against wildtype and CCR5-antibody
E Topics discussed will include improving antibody efficacy from initial target
resistant HIV-1 strains binding, and dual blockade of disease mediators with bispecific antibodies.
Jürgen Michael Schanzer The future of conjugated therapies, engineering enhanced PK/PD and the
Research Scientist Biologics Engineering impact of systems biology on clinical development will also be discussed.
Roche Diagnostics Join this lively session and email your questions for the panel to:
nicholas.stone@visiongainglobal.com
12:00 κ
λ-body: a manufacturing friendly bispecific
antibody format
• n contrast to other bispecific formats, κλ -Bodies are unmodified
I 16:40 Closing remarks from the Chair
fully human IgGs
• λ-Bodies rely on the assembly of a kappa and a lambda light
κ
chain with a common heavy chain
• Development of a streamlined platform for producingκλ-bodies
16:50 Networking drinks
Nicolas Fischer
Take your discussions further and build new
Head of Research
NovImmune relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

5. Day 2
5th Annual Recombinant Antibodies
Thursday 19th January 2012
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the Chair 13:40 Presentation to be announced
Paulo Fontoura Andrew Nesbitt
Global Head CNS Translational Medicine Associate Director, Cimzia Mechanism of Action Group
F. Hoffmann-La Roche UCB Celltech
09:40 Beyond natural antibodies: the power of in vitro 14:20 Monoclonal antibody therapy in multiple sclerosis:
display technologies paradigm shifts and emerging challenges
• Unique features of display technologies
• mAbs may offer considerable advantages over other therapies for MS
• Recognition of modifications in proteins, and cell surface receptors
• However, efficacy comes with significant clinical risks
• Exploiting the recombinant nature of in vitro selected mAbs
John McCafferty • btaining the best benefit-risk ratio, monitoring and preventing emergent
O
Director of Research safety concerns
University of Cambridge
15:00 Afternoon refreshments
10:20 Generation of differentiated
biological therapeutics
15:20 Generation of therapeutic antibodies against
• A review of biologics discovery at MedImmune
inflammatory disease and cancer targets, with a low
CASE STUDY
• Project case study examples will be given risk of clinical immunogenicity
• Examples of differentiated products will be included
Matthew Baker
Maria Groves Chief Scientific Officer
Senior Scientist, Lead Generation, ADPE Antitope
MedImmune
16:00 Conjugated mAbs for cancer treatment
11:00 Morning refreshments • Improved cytotoxic treatments
• Anti-tumour activity through target cell activation
11:20 On setting the first dose in man: quantitating • Evidence from in vivo trials
biotherapeutic drug-target binding through Christian Rohlff
pharmacokinetic and pharmacodynamic models Chief Executive Officer
• Contributions of in vitro and in vivo studies Oxford BioTherapeutics
• Roles and limitations of in vivo animal models
• Overcoming challenges for clinical pharmacology
16:40 Chair’s closing remarks
Jennifer Sims
Global Head of Biologics Safety Disposition
Novartis
16:50 End of conference
12:00 Modulation of Fc receptor function: from
principle to translation in the clinic
• c engineering resulting in decreased or increased effector function,
F
or half life extension
CASE STUDY
• Utility of translational PK/PD to predict human safety and efficacy
• Three examples illustrating issues arising during drug development
Lolke de Haan
Director of Toxicology, Biologics Safety Assessment
MedImmune

6. Registration Form
5th Annual Recombinant Antibodies
17th - 19th January 2012, London, UK
Angel
Conf. code PP Pentonville Road
5th Annual Recombinant
Ci
Standard Prices
ty
Antibodies
Ro
ad
Conference and workshop Fee: £1699 VAT: £339.80 Total: £2038.80
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80 17th - 19th January 2012
Old Street
Workshop only Fee: £599 VAT: £119.80 Total: £718.80
Location: Visiongain Conference Centre Old Street
Address:
Number of bookings: Total cost: 230 City Road
City Road
London
EC1V 2TT
Promotional Literature Distribution UK
Distribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £199.80 Total: £1198.80
How to book
Details Email: piyush.patel@visiongain.com
Web: http://www.visiongain.com/rabs
Forename: Surname: UK Office:
Tel: +44(0) 20 7549 9961
Job Title: Company: Fax: +44(0) 20 7549 9932
Visiongain Ltd
Main Switchboard Number: BSG House
230 City Road
London
Address: EC1V 2QY
UK
General information
Venue: Venue: Directions: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United
Country: Postcode: Kingdom. Closest tube station is Old Street (Northern Line).
Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376
Phone: Fax: 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343
http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html
Email: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207
628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Signature:
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
I confirm that I have read and agree to the terms and conditions of booking
right to charge interest on unpaid invoices.
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Methods of payment made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
after one month before the start of the event. Should you decide to cancel after this date, the full invoice
Payment must be made in sterling
must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
By Mail: Complete and return your signed registration form together with your cheque payable between conferences. However, if you cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email, fax or post. Name changes and
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK substitutions must be from the same company or organisation and are not transferable between
By Fax: Complete and fax your signed registration form with your credit card details countries. Please note that discounted delegates places at a visiongain event are non refundable.
to +44 (0) 20 7549 9932 Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
excluding substitutions/name changes, requested by the customer. This will be charged to the
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details customer by credit card prior to the changes being made.
Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932
briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
By Bank Transfer: due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
Visiongain Ltd A/C: visiongain Ltd expenses, which may be incurred by the customer as a consequence of the event being postponed or
Barclays Bank Sort Code: 20-71-64 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
Piccadilly Branch Account No: 6038 7118
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
48 Regent Street Swift Code: BARC GB22 Protection Act 1988. Your personal information contained in this form may be used to update you on
London, W1B 5RA IBAN: GB80 BARC 20716460387118 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
Please debit my credit card: wish for your details to be amended, suppressed or not passed on to any external third party, please
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Access MasterCard Visa American Express EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
Card number: visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
Expiry Date: recommend you obtain).
VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
Security number (last 3 digits on back of credit card): incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Signature: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Cardholder’s name: Unable to attend
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
News updates with your payment. You will receive speaker talks in PDFs two weeks after the event.
Please tick if you do not want to receive email news updates in the future Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
www.visiongain.com/rabs